Navigation Links
Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
Date:4/25/2011

merase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. PSI-7977, an unpartnered uracil nucleotide analog that is currently dosing in three Phase 2b studies in patients with HCV genotypes 1 through 6 and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and a 14-day combination study with PSI-7977. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and one interferon free combination trial. These clinical studies are being conducted through a strategic collaboration with Roche.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities an
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/12/2014)... Response Management Systems is a crucial peak load management ... energy supply and demand. With the help of DRMS, ... increasing pressure on the grid) and replaced by Advanced ... and thermostats for load reduction. , DRMS is ... government mandates and benefits for energy efficiency and conservation ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Casinos ... years, despite rising competition from international and online casinos. ... 2.9% over the five years through 2014-15. Greater per ... demanding more gaming services. Rises in discretionary income levels ... more money on non-essential items such as casino gambling ...
(Date:7/12/2014)... Canada (PRWEB) July 12, 2014 Sean Francis, owner ... throwing out special challenges to his clients. He’s also known for ... He recently found a way to combine the two and is ... raised $2,000 for the Boys and Girls Club. , The funds ... which started on June 23rd. Francis sent out emails and asked ...
(Date:7/12/2014)... With prom shopping reaching its final days, VogueQueen.com, a ... showcase its new and trendy apparels. Recently, the company ... its online shop. Additionally, it is now providing huge ... According to the company’s sales manager, the promotion will ... , He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with ... questions. Paddock tackles topics including main men's health ... longer than men, and testosterone replacement therapy, among others. ... featured on Doylestown Hospital’s website, Dr. Brad Paddock says, ... If you notice pain, bulging, or asymmetry in your ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... Hospital investigators have found that an electrically powered amplification ... to the acute hearing of humans and other mammals. ... loss can result from malfunction of this amplification machinery ... as aspirin. , Sound entering the cochlea is detected ...
... May 7 The following is a,statement by ... The guidelines for smoking cessation released today ... reminder to the nation,s 45 million,smokers that they ... quit smoking and protect their health than ever ...
... Presbyterian Hospital of,Plano has been named a recipient ... state,s highest honor for quality and organizational,performance., ... health care facility,in Collin County to receive this ... is the first hospital in parent company Texas ...
... thwarted rewiring needed for neural development, mouse study shows ... class of weight-loss drugs that suppresses appetite by blocking ... caution in children, U.S. scientists report. , In research ... suppresses the adaptive rewiring of the brain necessary for ...
... GAINESVILLE, Fla. Retinas in newborn mice appear perfectly fine ... microRNAs except for one thing the retinas do not ... the absence of microRNAs in the mammalian eye, an international ... the Italian National Research Council describes a gradual structural decline ...
... As part of its ongoing,commitment to providing the ... is excited to welcome Katherine Anne Binns as ... New York office. KN will,draw particularly on her ... growing list of clients., "Katherine possesses the ...
Cached Medicine News:Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 2Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 4Health News:Presbyterian Hospital of Plano Receives Prestigious Texas Award for Performance Excellence 2Health News:MicroRNAs appear essential for retinal health 2Health News:MicroRNAs appear essential for retinal health 3Health News:Senior Researcher With Extensive Healthcare Experience Joins Knowledge Networks 2
... throughput primary or backup instrument, this ... and reliability equal to or greater ... advanced technology of the AUTION JET ... reproducible and accurate results, limiting interference ...
... (E3) is one of the 3 major ... and estrone). In terms of estrogenic activity, ... [1]. Estriol is produced almost exclusively during ... in the normal human fetus. During pregnancy, ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... Estrone (E1) is one of the ... include estradiol and estriol. Estrone is produced ... adrenal cortex or gonads [1,2]. In premenopausal ... is secreted by the ovary. In prepubertal ...
Medicine Products: